1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6572980C7FBADF3C000258975003BC3CF
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-patient-driven-growth-maximizing-patient-co-creation?opendocument
18
19opendocument
203.233.219.103
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Patient Focused Services Patient-Centric Initiatives

Patient-Driven Growth: Maximizing Patient Co-Creation

ID: 5754


Features:

16 Info Graphics

12 Data Graphics

230+ Metrics

17 Narratives


Pages/Slides: 33


Published: 2023


Delivery Format: Online PDF Document


 

License Options:


Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from “Patient-Driven Growth: Maximizing Patient Co-Creation”

STUDY OVERVIEW

As biopharma organizations are driven towards increased patient-centricity, the concept of patient co-creation has presumed greater significance. Patient co-creation programs allow organizations to involve patients early at each stage – whether it is at R&D stage for the creation of lay summaries, developing a new drug or therapy, or co-developing education and support resources.

Best Practices, LLC undertook this benchmarking research to help biopharma leaders achieve patient-centric growth by examining innovative approaches and effective practices which are delivering high impact across patient co-creation. The study establishes benchmarks around patient co-creation programs, key design phases, engagement channels, high-impact areas, and innovative trends.

KEY TOPICS

  • Use of Patient Co-creation Programs
  • Effective Channels for Co-creation
  • Frequency of Co-Creation Insights Utilization

KEY METRICS

  • Do benchmark organizations leverage patient "co-creation" in the development of new initiatives?
  • What are benchmark organizations’ approach to patient co-creation?
  • Who primarily leads co-creation within benchmark organizations?
  • How effective are each of the listed channels for directly interacting and collaborating with patients to co-create new solutions?
  • How do brands or other teams utilize co-creation insights within benchmark organizations?
  • How often do internal teams utilize the insights from co-creation projects to make strategic or tactical decisions?

SAMPLE KEY FINDINGS

  • Use of Patient Co-Creation: 67% of benchmark companies currently use patient co-creation to develop new initiatives, with other companies planning to do so in the future. A quarter of companies use PCC for "most initiatives," while 42% of companies who use PCC for "some initiatives.”

METHODOLOGY

Best Practices, LLC engaged representatives from 26 biopharma companies in this benchmarking research study. To enhance the quality of research insights, nine qualitative interviews were conducted with high-performing benchmark participants.

Industries Profiled:
Biopharmaceutical; Pharmaceutical; Manufacturing; Biotech; Consumer Products; Diagnostic; Medical Device; Health Care; Clinical Research; Laboratories


Companies Profiled:
Alkermes; Astellas; AstraZeneca; Bayer; BELLUS Health; Biogen; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; CSL Behring; Debiopharm; Eli Lilly and Company; GlaxoSmithKline ; Janssen; Jazz Pharmaceuticals; Kala Pharmaceuticals; Inc.; Mitsubishi Tanabe Pharma Corporation; Novartis; Novo Nordisk; Organon; OTSUKA; Pfizer; Sanofi; Sunovion; Takeda Pharmaceuticals; UCB Pharma

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.